Teva Pharmaceuticals Industries Ltd (ADR) (NYSE:TEVA) has made an official and unsolicited bid for rival generic drugmaker Mylan NV (NASDAQ:MYL), offering $82/share in a combination …
On March 30, Teva Pharmaceuticals Industries Ltd (ADR) (NYSE:TEVA) announced they will be acquiring Auspex Pharmaceuticals Inc (NASDAQ:ASPX) in an all-cash transaction valued …
Israeli bio-tech company Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced on March 30th that it will acquire neurology drug company Auspex Pharmaceuticals Inc …
Some biopharma business development teams had a sleepless weekend. Four healthcare-related acquisitions were announced in quick succession on Monday morning, totaling about $18 billion …
In a research report issued today, Canaccord Genuity analyst Corey Davis reiterated a Hold rating on Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) with a …
In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Teva Pharmaceutical (NYSE:TEVA), but slightly reduced his …
In a research note released Friday, Deutsche Bank analyst Gregg Gilbert maintained a Buy rating on Teva Pharmaceutical (NYSE:TEVA) and slightly raised his price target to $65 …
In a report issued August 5, Maxim Group analyst Jason Kolbert provided an optimistic view on Teva Pharmaceuticals (TEVA) following the release of the company’s second-quarter results, …
Maxim Group analyst Jason Kolbert today issued a note in which he reiterated a Buy rating on Momenta Pharma (MNTA) with a $17 price target. Momenta continues …
In a research report issued Thursday, Canaccord analyst Corey Davis initiated coverage with a “Hold” rating on Teva Pharmaceutical Industries (TEVA) and a price target of $55.70 a share, based on the following: 1) valuation, …
